Heart Failure Clinical Trials

39 trials recruiting in Canada.

Heart & Circulation

Recruiting Drug Device Behavioral Older adults Healthy volunteers

35 trials · showing 30

Testing NT-proBNP with AI echocardiogram for heart failure

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives NT-proBNP, together with one or more of: AI echocardiogram, electrocardiogram and Cardiovascular physical examination. Group B receives no study treatment and is followed for comparison.

Sites in Montreal, Sherbrooke and 1 more city

2 groups
Sites in Vancouver, Montreal and 1 more city
Recruiting

Official title: Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure

Heart Failure · Cardiology Research UBC

Testing Omecamtiv Mecarbil (OM) against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Omecamtiv Mecarbil (OM). Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 11 more cities

Phase 3
2 groups
Sites in Edmonton, Kelowna and 11 more cities
Recruiting

Official title: Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Heart Failure · Cytokinetics

Testing Personalized cardiac pacing for heart failure with preserved ejection fraction (hfpef)

Explore this study →

There are 2 groups in this study. Group A receives Personalized cardiac pacing. Group B receives no study treatment and is followed for comparison.

Sites in Calgary and Vancouver

2 groups
Sites in Calgary and Vancouver
Recruiting

Official title: ELEVATE-HFpEF Clinical Study

Heart Failure With Preserved Ejection Fraction (HFpEF) · Medtronic Cardiac Rhythm and Heart Failure

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for heart failure.

Testing Maridebart cafraglutide against a placebo for heart failure with preserved ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives Maridebart cafraglutide. Group B, the placebo group, receives Placebo.

Sites in Cambridge, Toronto and 16 more cities

Phase 3
2 groups
Sites in Edmonton, Winnipeg and 15 more cities
Recruiting

Official title: Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction · Amgen

Testing vicadrostat with empagliflozin against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives vicadrostat and empagliflozin. Group B, the placebo group, receives placebo and empagliflozin.

Sites in Montreal, Cambridge and 14 more cities

Phase 3
2 groups
Sites in Cambridge, Hamilton and 14 more cities
Recruiting

Official title: A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Heart Failure · Boehringer Ingelheim

Testing vicadrostat with empagliflozin against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives vicadrostat and empagliflozin. Group B, the placebo group, receives Placebo and empagliflozin.

Sites in Québec, Brossard and 12 more cities

Phase 3
2 groups
Sites in Cambridge, Greater Sudbury and 12 more cities
Recruiting

Official title: A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Heart Failure · Boehringer Ingelheim

Testing Low Dose PF-07328948 against a placebo for heart failure

Explore this study →

There are 4 groups in this study. Group A, the placebo group, receives Placebo. Group B receives Low Dose PF-07328948. Group C receives Medium Dose PF-07328948. …and 1 more groups.

Sites in Greater Sudbury, Winchester and 10 more cities

Phase 2
4 groups
Sites in Richmond, Halifax and 9 more cities
Recruiting

Official title: A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure · Pfizer

Testing Baxdrostat and dapagliflozin for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Baxdrostat and dapagliflozin. Group B receives Placebo and dapagliflozin.

Sites in Toronto, Calgary and 27 more cities

Phase 3
2 groups
Sites in Calgary, Sherwood Park and 26 more cities
Recruiting

Official title: Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

Heart Failure · AstraZeneca

Comparing 3 approaches for heart failure and impaired kidney function

Explore this study →

There are 3 groups in this study. Group A receives balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg. Group B receives balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg. Group C, the comparison group, receives dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin.

Sites in Montreal, Cambridge and 20 more cities

Phase 3
3 groups
Sites in New Westminster, North Vancouver and 19 more cities
Recruiting

Official title: Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function · AstraZeneca

Testing Alleviant ALV1 System against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Alleviant ALV1 System. Group B, the sham group, receives Sham-Control.

Sites in Montreal, Newmarket and 1 more city

2 groups
Sites in Newmarket, Montreal and 1 more city
Recruiting

Official title: Alleviant ALLAY-HFrEF Study

Heart Failure · Alleviant Medical, Inc.

Testing CDR132L against a placebo for heart failure

Explore this study →

There are 4 groups in this study. Groups A, B and C receive CDR132L. Group D, the placebo group, receives Placebo.

Sites in Hamilton, Toronto and 6 more cities

Phase 2
4 groups
Sites in Vancouver, Brampton and 6 more cities
Recruiting

Official title: A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Heart Failure · Novo Nordisk A/S

Testing Colchicine with Thiamine Mononitrate against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives one or more of: Colchicine 0.5 MG and Colchicine placebo. Group B receives Thiamine Mononitrate 300 mg.

One site, in Hamilton

Phase 3
2 groups
One site, in Hamilton
Recruiting

Official title: COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

Heart Failure · Hamilton Health Sciences Corporation

Testing HJB647 low dose against a placebo for heart failure with reduced ejection fraction

Explore this study →

There are 3 groups in this study. Group A, the placebo group, receives Placebo. Group B receives HJB647 low dose. Group C receives HJB647 high dose.

One site, in Montreal

Phase 1
3 groups
One site, in Montreal
Recruiting

Official title: A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction · Novartis Pharmaceuticals

Testing Elecoglipron for heart failure with preserved ejection fraction (hfpef)

Explore this study →

There are 2 groups in this study. Group A receives Elecoglipron. Group B, the comparison group, receives Placebo.

Sites in London, Markham and 14 more cities

Phase 3
2 groups
Sites in Barrie, Etobicoke and 13 more cities
Recruiting

Official title: A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Heart Failure With Preserved Ejection Fraction (HFpEF) · AstraZeneca

Testing Finerenone against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone. Group B, the placebo group, receives Placebo.

Sites in Toronto, Edmonton and 12 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 11 more cities
Recruiting

Official title: A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Heart Failure · Colorado Prevention Center

Testing Finerenone with Empagliflozin for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone and Empagliflozin. Group B receives no study treatment and is followed for comparison.

Sites in Toronto, Edmonton and 6 more cities

Phase 3
2 groups
Sites in Edmonton, Surrey and 5 more cities
Recruiting

Official title: A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Heart Failure · Colorado Prevention Center

Testing Midodrine for heart failure with reduced ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives Midodrine Oral Tablet. Group B receives no study treatment and is followed for comparison.

One site, in Ottawa

Phase 2
2 groups
One site, in Ottawa
Recruiting

Official title: Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension

Heart Failure With Reduced Ejection Fraction · Ottawa Heart Institute Research Corporation

Testing Combined Epoprostenol Sodium & Milrinone against a placebo for right heart failure

Explore this study →

There are 2 groups in this study. Group A, the placebo group, receives Normal saline. Group B, the comparison group, receives Combined Epoprostenol Sodium & Milrinone.

One site, in Montreal

Phase 2
2 groups
One site, in Montreal
Recruiting

Official title: Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation

Right Heart Failure · Montreal Heart Institute

Testing Biomarker guided discharge algorithm for heart failure

Explore this study →

There are 2 groups in this study. Group A receives no study treatment and is followed for comparison. Group B receives Biomarker guided discharge algorithm.

One site, in Ottawa

2 groups
One site, in Ottawa
Recruiting

Official title: Biomarker Guided Discharge of Heart Failure Patients

Heart Failure; With Decompensation · Ottawa Heart Institute Research Corporation

Testing CardioMems for chronic heart failure

Explore this study →

There are 2 groups in this study. Group A receives no study treatment and is followed for comparison. Group B, the comparison group, receives CardioMems.

One site, in Montreal

2 groups
One site, in Montreal
Recruiting

Official title: Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes

Chronic Heart Failure · Montreal Heart Institute

Comparing Lower-body Negative Pressure (-25 mmHg) with Lower-body Negative Pressure (-15 mmHg) for heart failure with preserved ejection fraction

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Lower-body Negative Pressure (-25 mmHg), Lower-body Negative Pressure (-15 mmHg) and Lower-body Neutral Pressure (0 mmHg). Group B, the comparison group, receives one or more of: Lower-body Negative Pressure (-25 mmHg), Lower-body Negative Pressure (-15 mmHg) and Lower-body Neutral Pressure (0 mmHg).

One site, in Kelowna

2 groups
One site, in Kelowna
Recruiting

Official title: Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction · University of British Columbia

Comparing His/LBBP with BiVP for heart failure

Explore this study →

There are 2 groups in this study. Group A, the comparison group, receives His/LBBP. Group B, the comparison group, receives BiVP.

Sites in Montreal, Calgary and 11 more cities

2 groups
Sites in Edmonton, Vancouver and 11 more cities
Recruiting

Official title: Left vs Left Randomized Clinical Trial

Heart Failure · Baylor College of Medicine

Testing Alleviant ALV1 System against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Alleviant ALV1 System. Group B, the sham group, receives Sham-Control.

Sites in Montreal and Newmarket

2 groups
Sites in Newmarket and Montreal
Recruiting

Official title: Alleviant ALLAY-HF Study

Heart Failure · Alleviant Medical, Inc.

Comparing Virtual HF Care with Routine HF Care for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Virtual HF Care. Group B receives Routine HF Care.

Sites in Hamilton, Thunder Bay and 1 more city

2 groups
Sites in Hamilton, Thunder Bay and 1 more city
Recruiting

Official title: VIrtual Care To Improve Outcomes and RecoverY From Heart Failure Hospitalization

Heart Failure · Population Health Research Institute

Testing NT-proBNP for heart failure

Explore this study →

There are 2 groups in this study. Group A receives no study treatment and is followed for comparison. Group B receives NT-proBNP.

Sites in Montreal and Vancouver

2 groups
Sites in Vancouver and Montreal
Recruiting

Official title: Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"

Heart Failure · NHS Greater Glasgow and Clyde

Testing Finerenone against a placebo for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Finerenone. Group B, the placebo group, receives Placebo.

Sites in Edmonton, Toronto and 10 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 9 more cities
Recruiting

Official title: A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Heart Failure · Colorado Prevention Center

Testing Stopping Heart Failure Medication(s) for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Stopping Heart Failure Medication(s). Group B receives no study treatment and is followed for comparison.

Sites in Toronto, Edmonton and 3 more cities

Phase 4
2 groups
Sites in Edmonton, Winnipeg and 3 more cities
Recruiting

Official title: The STOP-MED CTRCD Trial

Heart Failure · Dinesh Thavendiranathan

Testing Social prescribing for heart failure

Explore this study →

There are 2 groups in this study. Group A receives Social prescribing. Group B receives no study treatment and is followed for comparison.

2 sites in Montreal

2 groups
2 sites in Montreal
Recruiting

Official title: Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure

Heart Failure · McGill University Health Centre/Research Institute of the McGill University Health Centre

Testing Levocarnitine for heart failure

Explore this study →

Everyone in this study is in one group and receives Levocarnitine.

One site, in London

Early Phase 1
1 group
One site, in London
Recruiting

Official title: Oral Carnitine in Heart Failure Patients

Heart Failure · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Testing Heart Failure and Mental Health for heart failure

Explore this study →

Everyone in this study is in one group and receives Heart Failure and Mental Health Intervention (FRAME).

Sites in Ottawa, Cornwall and 3 more cities

1 group
Sites in Cornwall, Limoges and 3 more cities
Recruiting

Official title: Improving Care and Mental Well-Being for Adults With Heart Failure

Heart Failure · Bruyère Health Research Institute.

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Heart Failure trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.